Zosano Pharma Corp
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $785,000 | $224,000 | $0 | $0 | $0 | $0 |
| Operating income | −$31.5M | −$32.8M | −$37.2M | −$35.4M | −$28.4M | −$28.6M |
| Net income | −$29.9M | −$33.4M | −$37.6M | −$35.4M | −$29.1M | −$29.8M |
| Total assets | $48.4M | $72.0M | $37.7M | $35.8M | $18.0M | $20.9M |
| Total liabilities | $15.4M | $24.5M | $28.3M | $17.1M | $11.0M | $16.4M |
| Equity | $33.0M | $47.5M | $9.4M | $18.7M | $7.0M | $4.5M |
| EPS (diluted) | $-0.27 | $-0.49 | — | — | — | — |
| Shares out. | 106.3M | 54.3M | 12.0M | 2.0M | 19.5M | 12.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −4016.8%
- Net margin
- −3812.1%
- Return on equity
- −90.8%
- Return on assets
- −61.8%
- Return on capital (ROCE)
- −84.6%
- Liabilities / assets
- 31.9%
- Debt / equity
- 0.47×
- Book value / share
- $0.31
- Revenue growth (YoY)
- 250.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -26.46distress
- Accruals / assets
- −4.8%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 15, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Matthews ChristineOfficer — Chief Financial Officer | Jun 6, 2022 | Sell | 82 | $0.71 |
| Lo StevenOfficer — Chief Executive Officer | Jun 6, 2022 | Sell | 442 | $0.71 |
| Matthews ChristineOfficer — Chief Financial Officer | Mar 31, 2022 | Sell | 8,116 | $0.21 |
| Kellerman Donald JOfficer — VP, Clinical Dev & Med Affairs | Mar 31, 2022 | Sell | 4,006 | $0.21 |
| Lo StevenOfficer — Chief Executive Officer | Mar 31, 2022 | Sell | 23,633 | $0.21 |
| Greathouse KennethDirector | Nov 23, 2021 | Sell | 10,000 | $0.60 |
| Kellerman Donald JOfficer — VP, Clinical Dev & Med Affairs | Oct 15, 2021 | Grant | 10,000 | $0.00 |
| Matthews ChristineOfficer — Chief Financial Officer | Oct 15, 2021 | Grant | 56,250 | $0.00 |
| Lo StevenOfficer — Chief Executive Officer | Oct 15, 2021 | Grant | 118,750 | $0.00 |
| Grais LindaDirector | Jun 10, 2021 | Grant | 15,000 | $0.00 |
| Elms SteveDirector | Jun 10, 2021 | Grant | 15,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeJun 3, 2022
- Terminated a material agreement · Bankruptcy or receivership · Other material eventJun 2, 2022
- Director / officer changeMay 18, 2022
- Results of operations · Director / officer changeMay 13, 2022
- Director / officer changeMay 5, 2022
- Other material eventApr 29, 2022
- Modified shareholder rights · Amended charter or bylaws · Shareholder vote · Other material eventApr 11, 2022
- Results of operationsMar 17, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 25-NSEJul 19, 2022
- 4FORM 4 SUBMISSIONJun 7, 2022
- 4FORM 4 SUBMISSIONJun 7, 2022
- 8-KJun 3, 2022
- 8-KJun 2, 2022
- SC 13GSCHEDULE 13GMay 18, 2022
- 8-KMay 18, 2022
- 10-QMay 13, 2022
- 8-KMay 13, 2022
- 8-KMay 5, 2022
- 8-KApr 29, 2022
- 10-K/AApr 29, 2022
- 8-KApr 11, 2022
- 4FORM 4Apr 1, 2022
- 4FORM 4Apr 1, 2022
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.